Cape Investment Advisory Inc. Trims Stake in IQVIA Holdings Inc. (NYSE:IQV)

Cape Investment Advisory Inc. lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,295 shares of the medical research company’s stock after selling 63 shares during the quarter. Cape Investment Advisory Inc.’s holdings in IQVIA were worth $1,630,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Nisa Investment Advisors LLC boosted its position in shares of IQVIA by 4.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 11,346 shares of the medical research company’s stock valued at $2,689,000 after acquiring an additional 530 shares during the last quarter. US Bancorp DE lifted its position in IQVIA by 62.2% during the third quarter. US Bancorp DE now owns 27,061 shares of the medical research company’s stock valued at $6,413,000 after purchasing an additional 10,379 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in shares of IQVIA by 35.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 407 shares of the medical research company’s stock worth $96,000 after buying an additional 106 shares during the last quarter. Chicago Partners Investment Group LLC purchased a new stake in shares of IQVIA during the 3rd quarter valued at $218,000. Finally, Optas LLC purchased a new position in IQVIA in the third quarter worth $210,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Activity

In other news, Director John G. Danhakl acquired 1,275 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. JPMorgan Chase & Co. decreased their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Morgan Stanley lifted their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Four analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $251.22.

IQVIA Stock Performance

Shares of IQV stock opened at $188.89 on Friday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a fifty day moving average of $199.13 and a 200 day moving average of $214.80. The firm has a market capitalization of $33.26 billion, a price-to-earnings ratio of 25.19, a PEG ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 52 week low of $184.66 and a 52 week high of $261.73.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.